Navigation Links
Amarin Announces Completion of the First Tranche of $60 Million Private Placement
Date:5/22/2008

don, Ph. D., CFA, is a founding General Partner and Co-Head of Private Equity of OrbiMed Advisors LLC. Dr. Gordon is active in both private equity and small-capitalization public equity investments. He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995. Dr. Gordon received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology. His doctoral work involved studies of protein folding and assembly. He received a Bachelors degree from Harvard College.

Dr. Eric Aguiar is a Partner at Thomas, McNerney & Partners. He has 16 years of experience in the biopharmaceutical industry. From 2001 to 2007 he was a Managing Director at HealthCare Ventures. Prior to joining HealthCare Ventures, he was CEO of Genovo, Inc. Dr. Aguiar was an executive at TheraTech, a drug delivery company that was sold to Watson Pharmaceuticals in 1997. He was a Managing Director and Vice President of Philadelphia Ventures in the mid-1990's. Prior board seats have included CardioKine, SkinMedica, Vaxinnate, Metaphore Pharmaceuticals, 3-D Pharmaceuticals, and ThromboSys. He graduated from Harvard Medical School and Cornell University with honors.

Dr. Srinivas Akkaraju is a founding Managing Director of Panorama Capital and focuses primarily on life sciences investments. Previously, he was with J.P. Morgan Partners, serving as a Principal, starting in April 2001 and becoming a Partner in January 2005. From 1998 to 2001, Dr. Akkaraju was in Business and Corporate Development at Genentech, Inc., most recently as Senior Manager responsible for worldwide partnering activities, in-licensing of therapeutics, and out-licensing of development projects. In addition to his business development role, Dr. Akkaraju also served as a Project Team Leader for one of Genentech's clinical development products. During this time, he also was a founding member of BioStreet, an online marketplace for biotech op
'/>"/>

SOURCE Amarin Corporation Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amarin Announces Financial Results for Fourth Quarter and Full Year 2007
2. Amarin Secures Global Intellectual Property Rights for Lipid Programs
3. Amarin Appoints Dr. William Mason as Lead Independent Director
4. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
5. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
6. Amarin Signs Agreement to Acquire Ester Neurosciences
7. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
8. Amarin Announces Initiation of Cardiovascular Development Strategy
9. Amarin to Present at 4th Annual Bio Investor Forum
10. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
11. AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... DIEGO , Aug. 3, 2015  Halozyme Therapeutics, ... Update Conference Call for the second quarter 2015 on ... PT. Dr. Helen Torley , president and chief ... date post-market, Halozyme will release financial results for the ... webcast live through the "Investors" section of Halozyme,s corporate ...
(Date:8/3/2015)... 3, 2015  Merck KGaA, Darmstadt, Germany ... high-tech products in the healthcare, life science and performance ... Nano-C, their development and launch of promising new fullerene ... Merck KGaA, Darmstadt, Germany , is ... sector. Novel derivatives: highly stable, easy to ...
(Date:8/3/2015)... NEW YORK , August 3, 2015 ... "Global Market Study on 3D Cell Culture: ... published by Persistence Market Research, the global 3D cell culture ... is expected to expand at a CAGR of 29.1% ... View Full Report with TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp ...
(Date:7/31/2015)... China Cord Blood Corporation (NYSE: CO) ("CCBC" ... provider of cord blood collection, laboratory testing, hematopoietic stem ... that the Company has filed its Annual Report on ... The filed Form 20-F includes audited financial statements for ... 20-F can be accessed by visiting the U.S. Securities ...
Breaking Biology Technology:Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4China Cord Blood Corporation Files Its Annual Report on Form 20-F 2
... Monogram,Biosciences, Inc. (Nasdaq: MGRM ) today ... the company,s HIV tropism assay were presented in,an ... Resistance Workshop,in Sitges, Spain. Trofile was introduced commercially ... class CCR5 antagonist, in,August 2007. Recent enhancements to ...
... CFO of Thermage Inc. To, Drive Coapt,s ... ALTO, Calif., June 13 Coapt Systems, Inc.,developer of ... the,plastic, reconstructive and sports medicine markets, announced today the,appointment ... will also,serve as a member of the company,s Board ...
... acquisition system offers revolutionary orthotic prescription ... ... PAL Health Technologies will,debut the new Xtremityscan System and give away ... June 19-22 at the,Disneyland Hotel., Xtremityscan is a digital shape ...
Cached Biology Technology:Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 2Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 3Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 4Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 5Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 6Coapt Systems New CEO, Laureen DeBuono, to Fuel Company's Growth and Product Innovation 2Coapt Systems New CEO, Laureen DeBuono, to Fuel Company's Growth and Product Innovation 3PAL Health Technologies Debuts Xtremityscan System at Western Podiatric Medical Congress 2
(Date:7/31/2015)... 31. juli 2015 Den 10. internationale konference ... BGI fra den 22. - 25. oktober i ... sin 10-års fødselsdag i år. Siden starten i 2006 ... møder på ,omik,-feltet, og er en af de mest ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden for ...
(Date:7/31/2015)... , 31. Juli 2015 Die 10. internationale Konferenz ... BGI veranstaltet und findet vom 22. bis 25. ... , statt. Die Konferenz feiert ... Start 2006 ist die ICG weltweit zu einem ... Sie ist eines der dynamischsten, enthusiastischsten und angenehmsten ...
(Date:7/27/2015)... July 27, 2015   Zynx Health ™, ... clinical improvement solutions, today announced that its ... available on Android smartphones and tablets. With this ... organizations can use ZynxCarebook to securely exchange messages ... streamline care transitions to other care settings, and ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... collaborative team of researchers at The University of Texas ... from the National Science Foundation (NSF) to establish the ... computer-based research, education and training. The five-year grant, ... Act, is the largest stimulus award UTSA has received ...
... In biology, ,signal transduction, refers to any process by ... stimulus into another. Most processes of signal transduction involve ... are carried out by enzymes and activated by second ... are usually rapid, lasting on the order of milliseconds ...
... on the cover of the September 2009 print issue of ... Australian scientists developed a new gene therapy vector that uses ... into our cells. As a result of this achievement, therapeutic ... efficiently than in the past, raising hopes for more effective ...
Cached Biology News:UTSA wins $5 million for new Simulation, Visualization and Real-Time Prediction Center 2Finding the ZIP-code for gene therapy: Scientists imitate viruses to deliver therapeutic genes 2
... combines 2 products into 1:, , A ... isolation kit , ,The FastPrep System ... Qbiogene/BIO101 System Matrix and Isolation Kits. Samples ... tubes eliminating the use of metal probes ...
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
Sterile, individually wrapped, 4mm Cuvettes...
... III RNase H- Reverse ... improved version of SuperScript™ ... Like SuperScript™ II it ... strand from single-stranded RNA ...
Biology Products: